SG11202013016YA - Heterocyclic compounds as trk inhibitors - Google Patents
Heterocyclic compounds as trk inhibitorsInfo
- Publication number
- SG11202013016YA SG11202013016YA SG11202013016YA SG11202013016YA SG11202013016YA SG 11202013016Y A SG11202013016Y A SG 11202013016YA SG 11202013016Y A SG11202013016Y A SG 11202013016YA SG 11202013016Y A SG11202013016Y A SG 11202013016YA SG 11202013016Y A SG11202013016Y A SG 11202013016YA
- Authority
- SG
- Singapore
- Prior art keywords
- heterocyclic compounds
- trk inhibitors
- trk
- inhibitors
- heterocyclic
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810660162.6A CN110627812B (zh) | 2018-06-25 | 2018-06-25 | 作为trk抑制剂的杂环化合物 |
| PCT/CN2019/092653 WO2020001415A1 (zh) | 2018-06-25 | 2019-06-25 | 作为trk抑制剂的杂环化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202013016YA true SG11202013016YA (en) | 2021-02-25 |
Family
ID=68966871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202013016YA SG11202013016YA (en) | 2018-06-25 | 2019-06-25 | Heterocyclic compounds as trk inhibitors |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11878987B2 (es) |
| EP (1) | EP3822276A4 (es) |
| JP (1) | JP7372686B2 (es) |
| KR (1) | KR20210024043A (es) |
| CN (1) | CN110627812B (es) |
| AU (1) | AU2019296085B2 (es) |
| BR (1) | BR112020026653A2 (es) |
| CA (1) | CA3104377C (es) |
| MX (1) | MX2020013694A (es) |
| PH (1) | PH12020552244A1 (es) |
| SG (1) | SG11202013016YA (es) |
| TW (1) | TWI828712B (es) |
| WO (1) | WO2020001415A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7092405B2 (ja) * | 2018-04-16 | 2022-06-28 | 深▲チェン▼市塔吉瑞生物医薬有限公司 | キナーゼ活性を阻害するためのジ（ヘテロ）アリール大環状化合物 |
| CN110627812B (zh) | 2018-06-25 | 2022-10-11 | 北京诺诚健华医药科技有限公司 | 作为trk抑制剂的杂环化合物 |
| WO2021042890A1 (zh) * | 2019-09-04 | 2021-03-11 | 罗欣药业(上海)有限公司 | 杂环化合物及其作为Trk激酶抑制剂的应用 |
| CN115884776B (zh) * | 2021-06-15 | 2024-07-23 | 中国医药研究开发中心有限公司 | 杂环大环化合物及其医药用途 |
| CN113444070A (zh) * | 2021-07-28 | 2021-09-28 | 深圳市真味生物科技有限公司 | 一种由手性叔丁基亚磺酰胺合成手性尼古丁的制备方法 |
| CN116554203A (zh) | 2022-01-29 | 2023-08-08 | 南京天印健华医药科技有限公司 | 化合物的晶型及其制备方法 |
| CN117586277A (zh) * | 2022-08-09 | 2024-02-23 | 苏州朗睿生物医药有限公司 | 一种大环三氮唑衍生物及其制备方法和用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0919873B8 (pt) | 2008-10-22 | 2021-05-25 | Array Biopharma Inc | compostos de pirazol[1,5-a]pirimidina substituídos como inibidores da trk quinase, seus processos de preparação e composições farmacêuticas |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| LT3205654T (lt) | 2010-05-20 | 2019-05-27 | Array Biopharma, Inc. | Makrocikliniai junginiai kaip trk kinazės slopikliai |
| JP6082397B2 (ja) | 2011-09-30 | 2017-02-15 | イプセン ファルマ ソシエテ パール アクシオン サンプリフィエＩｐｓｅｎ Ｐｈａｒｍａ Ｓ．Ａ．Ｓ． | マクロ環状ｌｒｒｋ２キナーゼ阻害剤 |
| HRP20221518T1 (hr) | 2014-01-24 | 2023-02-17 | Turning Point Therapeutics, Inc. | Diaril makrociklični spojevi kao modulatori protein kinaza |
| EP3368039A1 (en) | 2015-10-26 | 2018-09-05 | The Regents of The University of Colorado, A Body Corporate | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| TW201927790A (zh) * | 2017-11-10 | 2019-07-16 | 美商安捷克斯製藥公司 | 作為trk激酶抑制劑之巨環化合物及其用途 |
| TW201932472A (zh) | 2018-01-30 | 2019-08-16 | 大陸商上海吉倍生物技術有限公司 | 具有大環分子結構的化合物及其用途 |
| CN110156813B (zh) | 2018-02-13 | 2023-07-25 | 北京诺诚健华医药科技有限公司 | 作为trk抑制剂的杂环化合物 |
| JP7092405B2 (ja) | 2018-04-16 | 2022-06-28 | 深▲チェン▼市塔吉瑞生物医薬有限公司 | キナーゼ活性を阻害するためのジ（ヘテロ）アリール大環状化合物 |
| CN110627812B (zh) | 2018-06-25 | 2022-10-11 | 北京诺诚健华医药科技有限公司 | 作为trk抑制剂的杂环化合物 |
-
2018
- 2018-06-25 CN CN201810660162.6A patent/CN110627812B/zh active Active
-
2019
- 2019-06-25 US US17/255,797 patent/US11878987B2/en active Active
- 2019-06-25 JP JP2020572445A patent/JP7372686B2/ja active Active
- 2019-06-25 EP EP19825716.4A patent/EP3822276A4/en active Pending
- 2019-06-25 WO PCT/CN2019/092653 patent/WO2020001415A1/zh unknown
- 2019-06-25 SG SG11202013016YA patent/SG11202013016YA/en unknown
- 2019-06-25 BR BR112020026653-1A patent/BR112020026653A2/pt unknown
- 2019-06-25 AU AU2019296085A patent/AU2019296085B2/en active Active
- 2019-06-25 TW TW108122091A patent/TWI828712B/zh active
- 2019-06-25 KR KR1020217001867A patent/KR20210024043A/ko not_active Application Discontinuation
- 2019-06-25 MX MX2020013694A patent/MX2020013694A/es unknown
- 2019-06-25 CA CA3104377A patent/CA3104377C/en active Active
-
2020
- 2020-12-22 PH PH12020552244A patent/PH12020552244A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019296085B2 (en) | 2024-02-15 |
| KR20210024043A (ko) | 2021-03-04 |
| US20210147445A1 (en) | 2021-05-20 |
| CA3104377C (en) | 2024-01-23 |
| MX2020013694A (es) | 2021-05-27 |
| EP3822276A4 (en) | 2022-04-06 |
| WO2020001415A1 (zh) | 2020-01-02 |
| US11878987B2 (en) | 2024-01-23 |
| CA3104377A1 (en) | 2020-01-02 |
| TW202019939A (zh) | 2020-06-01 |
| BR112020026653A2 (pt) | 2021-03-23 |
| TWI828712B (zh) | 2024-01-11 |
| JP2021529182A (ja) | 2021-10-28 |
| PH12020552244A1 (en) | 2021-06-28 |
| AU2019296085A1 (en) | 2021-01-28 |
| EP3822276A1 (en) | 2021-05-19 |
| JP7372686B2 (ja) | 2023-11-01 |
| CN110627812A (zh) | 2019-12-31 |
| CN110627812B (zh) | 2022-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276509A (en) | Heterocyclic compounds as kinase inhibitors | |
| IL274762A (en) | Novel heterocyclic compounds as PRMT5 inhibitors | |
| IL290508A (en) | Heterocyclic compounds as kinase inhibitors | |
| ZA202003528B (en) | Substituted bicyclic heterocyclic compounds as prmt5 inhibitors | |
| SG11202013016YA (en) | Heterocyclic compounds as trk inhibitors | |
| IL280821A (en) | Heterocycline compound | |
| EP3297437A4 (en) | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF KINASES | |
| IL289389A (en) | Heterocyclic compounds as kinase inhibitors | |
| IL282659A (en) | Heterocyclic compounds as bet inhibitors | |
| IL289617A (en) | Heterocyclic compounds | |
| EP3720495A4 (en) | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | |
| IL289595A (en) | Heterocyclic compounds | |
| EP3666770A4 (en) | NEW HETEROCYCLIC COMPOUNDS AS CDK8 / 19 INHIBITORS | |
| IL266789A (en) | Heterocyclic compounds as kinase inhibitors | |
| ZA202104402B (en) | Heterocyclic compound | |
| SG11202009356RA (en) | Heterocyclic compound | |
| IL280292A (en) | Spiro-heterocyclic substances and their use as MAGL inhibitors | |
| GB201915191D0 (en) | Novel heterocyclic compounds | |
| HK1252918A1 (zh) | 作為erk抑制劑的雜環化合物 | |
| IL277340A (en) | The orthocyclic compound | |
| GB201808580D0 (en) | Heterocyclic compounds | |
| HK1245261A1 (zh) | 作為fgfr抑制劑的雜環化合物 | |
| GB201806488D0 (en) | Heterocyclic TADF compounds |